ACOG Key Statistics, Chart & Performance
The current stock price of ACOG is 6.5 USD. In the past month the price increased by 13.64%. In the past year, price increased by 14.64%.
ACOG Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About ACOG
Company Profile
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
Company Info
ALPHA COGNITION INC
c/o 1200 - 750 West Pender Street
Vancouver BRITISH COLUMBIA CA
Employees: 52
Phone: 16045649244
ALPHA COGNITION INC / ACOG FAQ
Can you describe the business of ALPHA COGNITION INC?
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company is headquartered in Vancouver, British Columbia and currently employs 52 full-time employees. The company went IPO on 2021-06-09. The firm's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
What is the stock price of ALPHA COGNITION INC today?
The current stock price of ACOG is 6.5 USD. The price decreased by -1.52% in the last trading session.
What is the dividend status of ALPHA COGNITION INC?
ACOG does not pay a dividend.
What is the ChartMill rating of ALPHA COGNITION INC stock?
ACOG has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the market capitalization of ACOG stock?
ALPHA COGNITION INC (ACOG) has a market capitalization of 141.31M USD. This makes ACOG a Micro Cap stock.
What is the ownership structure of ALPHA COGNITION INC (ACOG)?
You can find the ownership structure of ALPHA COGNITION INC (ACOG) on the Ownership tab.
ACOG Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ACOG. When comparing the yearly performance of all stocks, ACOG turns out to be only a medium performer in the overall market: it outperformed 47.54% of all stocks.
ACOG Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ACOG. While ACOG has a great health rating, there are worries on its profitability.
ACOG Financial Highlights
Over the last trailing twelve months ACOG reported a non-GAAP Earnings per Share(EPS) of -1.37. The EPS increased by 52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.06% | ||
| ROE | -57.42% | ||
| Debt/Equity | 0 |
ACOG Forecast & Estimates
7 analysts have analysed ACOG and the average price target is 18.36 USD. This implies a price increase of 182.46% is expected in the next year compared to the current price of 6.5.